이부프로펜 정맥주사(IV) 시장 : 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global Intravenous Ibuprofen Market reached a valuation of USD 7.6 billion in 2024 and is forecasted to expand at an impressive CAGR of 8.6% between 2025 and 2034. This growth trajectory reflects the rising prevalence of chronic and acute conditions, including arthritis, cardiovascular diseases, and specific cancers, which frequently necessitate effective pain management solutions like intravenous ibuprofen. Additionally, advancements in healthcare infrastructure, increasing awareness about non-opioid pain management alternatives, and innovations in intravenous drug formulations are bolstering market expansion. The demand for quick, effective, and safe analgesic solutions across diverse medical settings continues to grow, positioning intravenous ibuprofen as a preferred option for healthcare providers worldwide.

The market comprises two primary product categories: conventional intravenous ibuprofen and high-concentration intravenous ibuprofen. Conventional intravenous ibuprofen, accounting for 71.3% of the market share in 2024, remains the dominant product type due to its widespread use for rapid pain relief, especially in emergency rooms and post-surgical scenarios. Its proven efficacy and safety profile have solidified its place as a trusted solution among medical professionals. The ease of administration and immediate impact in managing pain make it an indispensable tool in modern healthcare, driving continued growth for this segment.

Segmented by age group, the market serves both pediatric and adult populations, with adults generating USD 5 billion in 2024 alone. The aging population, particularly those dealing with chronic pain conditions such as arthritis and musculoskeletal disorders, is driving significant demand for intravenous ibuprofen. This demographic shift underscores the increasing reliance on fast-acting pain relief options, especially as healthcare providers prioritize minimizing patient discomfort in clinical and outpatient settings. With the elderly population expanding globally, the adult segment is expected to maintain its dominance over the forecast period.

In the United States, the intravenous ibuprofen market is projected to grow substantially, reaching USD 6.9 billion by 2034. Factors fueling this growth include the high prevalence of post-surgical pain, musculoskeletal disorders, and other injury-related conditions. The U.S. healthcare system's focus on effective pain management solutions and the large patient base amplifies the demand for intravenous ibuprofen. Regulatory endorsements further support this trend. Government and health authority communications have emphasized the efficacy of intravenous ibuprofen in treating mild to moderate pain and its complementary role alongside opioid analgesics for severe pain management. This regulatory backing enhances healthcare providers' confidence, making intravenous ibuprofen a trusted and preferred option in pain relief protocols across the nation.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of post-operative pain
    • 3.2.1.2 Advancements in non-opioid pain management
    • 3.2.1.3 Rising admissions in emergency and acute care departments
    • 3.2.1.4 Advances in intravenous drug delivery technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost compared to oral alternatives
    • 3.2.2.2 Potential side effects and contraindications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Conventional IV ibuprofen
• 5.3 High-concentration IV ibuprofen

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Fever management

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatrics
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AFT Pharmaceuticals
• 10.2 Al Nabeel International
• 10.3 Alveda Pharmaceuticals
• 10.4 CSL Limited
• 10.5 Cumberland Pharmaceuticals
• 10.6 Fresenius SE & Co. KGaA
• 10.7 Grifols
• 10.8 Harbin Gloria Pharmaceuticals
• 10.9 Hyloris Pharmaceuticals
• 10.10 Laboratorios Valmorca
• 10.11 Recordati
• 10.12 Sandor Medicaids
• 10.13 Soho Industri Pharmasi
• 10.14 Teligent
• 10.15 XGEN Pharmaceuticals